Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.40 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.38 |
| ▸ | KDM5A | P29375 | 3/20 | 0.38 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940220 | 0.81 | DHODH (0.40) | DHODHRUNX1KDM5AKDM4AKDM4C | |
| SCHEMBL940058 | 0.79 | KDM5A (0.37) | KDM5AKDM4AKDM4CKDM5B | |
| SCHEMBL939201 | 0.76 | CNR2 (0.38) | DHODHDDR1KDM4ECNR2TRPM8 | |
| SCHEMBL938974 | 0.75 | KDM5A (0.34) | DHODHKDM5AKDM4AKDM4CKDM4E | |
| SCHEMBL941263 | 0.73 | KDM4C (0.39) | DHODHKDM5AKDM4AKDM4CKDM4E | |
| SCHEMBL940188 | 0.73 | CLCN2 (0.38) | KDM5AKDM4AKDM4CKDM5BAKR1C2 | |
| SCHEMBL11947897 | 0.71 | DYRK1A (0.41) | KDM5AKDM4AKDM4CCNR2EGLN1 | |
| SCHEMBL937934 | 0.69 | ALDH1A1 (0.40) | KDM5AKDM4CKDM4EKDM5B | |
| SCHEMBL505489 | 0.68 | DHODH (0.57) | DHODHRUNX1KDM4CAKR1C2AKR1C1 | |
| SCHEMBL505208 | 0.67 | DHODH (0.70) | DHODHRUNX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440542-B1 | Substituted benzimidazoles, benzonthiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | DHODH 3459/4885RUNX1 1495/4885DDR1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.